Mometason Bei Heuschnupfen 1 A Pharma (Mometasone Furoate Ph. Eur.)

Mometasone furoate binds to glucocorticoid receptors inside nasal mucosal cells. The drug‑receptor complex moves into the cell nucleus and alters gene expression, suppressing inflammatory cytokines, chemokines and enzymes. This reduces swelling, mucus production and immune cell infiltration, providing relief from allergy‑related nasal symptoms.

The exact dosing regimen for Mometason Bei Heuschnupfen is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Patients should follow the prescriber’s instructions and the product label for the number of sprays per nostril and frequency of use.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To request Mometason Bei Heuschnupfen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency intranasal glucocorticoid with a favorable safety profile when used at recommended doses. Compared with older agents such as beclomethasone, it offers similar or greater anti‑inflammatory efficacy with a lower risk of systemic absorption, making it a preferred option for many clinicians.

Store Mometason Bei Heuschnupfen at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product after the expiration date printed on the label.

The spray is administered directly into each nostril. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press down on the actuator while breathing in gently through the nose. The same procedure is repeated for the other nostril as directed by the prescriber.

Serious but rare risks include nasal septal perforation, adrenal suppression with prolonged high‑dose use, and ocular complications such as glaucoma or cataracts. Patients should report persistent nosebleeds, visual changes, severe headache or signs of systemic steroid effects to their healthcare provider promptly.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or those for whom systemic corticosteroid therapy is contraindicated, unless specifically advised by a physician.